StimLabs Unveils Architect Fx to Transform Treatment of Complex and Chronic Wounds
Published: 04 Mar 2026
Author: Precedence Research
StimLabs has reported the introduction of Architect Fx, which is an advanced equine-pericardium-derived extracellular collagen matrix that possesses features to meet clinical needs. The new product is a major addition to the portfolio of the regenerative medicine offerings of the company and targets. This enhances the outcomes in patients with large, complex, and hard-to-heal wounds. As more people have developed chronic conditions like diabetes and vascular disease, advanced wound care solution is now becoming an important ingredient in contemporary healthcare systems. Architect Fx has positioned StimLabs to lead in this fast-changing industry.
Architect Fx has FDA 510(k) clearance for the usage of wound in a wide wound range that includes chronic diabetic wounds, venous leg wounds, and pressure wounds. The StimLabs proprietary BriDGE(r) technology has been used to stabilise the matrix, retaining the integrity of the extracellular matrix (ECM) and improving the strength of the matrix in the wound environment. The product prevents structural support of cellular infiltration and tissue remodelling, which are important to wound healing by resisting premature degradation.
The Architect Fx demonstrates the underlying strategic direction that StimLabs has towards innovation that is a direct response to unmet clinical needs. Chronic wounds continue to be a major challenge to the health care systems of many countries. Their incidence usually results in increased hospitalizations, re-hospitalizations, and poor quality of life among the affected patients. The developments of more sophisticated biologic materials, including Architect Fx, are supposed to speed up the recovery process. They minimize complications and possibly even decrease the expenses of treatment. StimLabs is strengthening its home of providing regenerative products with balance to ensure structural strength and bio-compatibility by providing a solution that is clinically efficient and operationally viable.
Echoing this sentiment, Tom Dion, Executive Vice President and Chief Commercial Officer of StimLabs, highlighted the strategic importance of the new product. “This product launch supports our strategy to expand both our commercial footprint and our product portfolio,” he noted. “Architect offers a rare combination of durability, flexibility, and clinical efficiency-giving providers control over how they manage complex wounds. It’s a solution designed with both patients and clinicians in mind, and it positions StimLabs for continued success in the advanced wound care space.” His comments reflect the company’s dual focus on innovation and market growth.